Human Experimentation and Research (International Library of Medicine, Ethics, and Law)

Human Experimentation and Research (International Library of Medicine, Ethics, and Law)

  • ただいまウェブストアではご注文を受け付けておりません。 ⇒古書を探す
  • 製本 Hardcover:ハードカバー版/ページ数 500 p.
  • 言語 ENG
  • 商品コード 9780754622260
  • DDC分類 174.28

Full Description


Human experimentation is essential to advance scientific knowledge and thereby improve the longevity and quality of human lives. This text covers some of the legal, technical, ethical and moral problems raised by human experimentation.

Table of Contents

Acknowledgements                                   ix
Series Preface xii
Introduction: Human Research Ethics xv
PART I THE HISTORICALAND PHILOSOPHICAL
FOUNDATIONS
1 Hans Jonas (1969), 'Philosophical 3 (30)
Reflections on Experimenting with Human
Subjects', Daedalus, 98, pp. 219-47.
2 Ruth Macklin and Susan Sherwin (1975), 33 (38)
'Experimenting on Human Subjects:
Philosophical Perspectives', Case Western
Reserve Law Review, 25, pp. 434-71.
3 Eric M. Meslin, Heather J. Sutherland, 71 (20)
James V. Lavery and James E. Till (1995),.
'Principlism and the Ethical Appraisal of
Clinical Trials', Bioethics, 9, pp. 399-418.
4 David J. Rothman (1998), 'The Nuremberg 91 (10)
Code in Light of Previous Principles and
Practices in Human Experimentation', in
Ulrich Tr ler and Stella Reiter-Theil in
cooperation with Eckhard Herych (eds),
Ethics Codes in Medicine: Foundations and
Achievements of Codification since 1947,
Ashgate: Aldershot, pp. 50-59.
5 James F. Childress (2000), 'Nuremberg's 101(16)
Legacy: Some Ethical Reflections',
Perspectives in Biology and Medicine, 43,
pp. 347-61.
6 Allen Buchanan (1996), 'The Controversy 117(6)
over Retrospective Moral Judgment', Kennedy
Institute of Ethics Journal, 6, pp. 245-50.
7 Tom L. Beauchamp (1996), 'Looking Back 123(20)
and Judging Our Predecessors', Kennedy
Institute of Ethics Journal, 6, pp. 251-70.
8 Arthur L. Caplan (1992), 'When Evil 143(4)
Intrudes', Hastings Center Report, 22, pp.
29-32.
9 Sissela Bok (1995), 'Shading the Truth in 147(18)
Seeking Informed Consent for Research
Purposes', Kennedy Institute of Ethics
Journal, 5, pp. 1-17.
10 Nancy E. Kass, Jeremy Sugarman, Ruth Faden 165(6)
and Monica Schoch-Spana (1996), 'Trust: The
Fragile Foundation of Contemporary Biomedical
Research', Hastings Center Report, 26, pp.
25-29.
11 George J. Annas (1996), 'Questing for 171(28)
Grails: Duplicity, Betrayal and Self
Deception in Postmodern Medical Research',
Journal of Contemporary Health Law and
Policy, 12, pp. 297-324.
12 David N. Weisstub (1996), 'Roles and 199(26)
Fictions in Clinical and Research Ethics',
Health Law Journal, 4, pp. 259-82.
PART II PROTECTING HUMAN SUBJECTS
13 Jay Katz (1993), 'Human Experimentation 225(48)
and Human Rights', Saint Louis University Law
Journal, 38, pp. 7-54.
14 Paul R. Benson (1989), 'The Social Control 273(12)
of Human Biomedical Research: An Overview and
Review of the Literature', Social Science and
Medicine, 29, pp. 1-12.
15 Jonathan D. Moreno (2001), 'Goodbye to All 285(10)
That: The End of Moderate Protectionism in
Human Subjects Research', Hastings Center
Report, 31, pp. 9-17.
16 Alexander Morgan Capron (1999), 'Is 295(10)
National, Independent Oversight Needed for
the Protection of Human Subjects?',
Accountability in Research, 7, pp. 283-92.
17 Anna C. Mastroianni (1999), 'National, 305(8)
Independent Oversight: Reinforcing the Safety
Net for Human Subjects Research',
Accountability in Research, 7, pp. 303-309.
18 Marshall B. Kapp (2002), 'Regulating 313(18)
Research for the Decisionally Impaired:
Implications for Mental Health
Professionals', Journal of Clinical
Geropsychology, 8, pp. 35-51.
19 Robert Michels (1999), 'Are Research 331(4)
Ethics Bad for Our Mental Health?', New
England Journal of Medicine, 340, pp. 1427-30.
20 George F. Tomossy and David N. Weisstub 335(30)
(1997), 'The Reform of Adult Guardianship
Laws: The Case of Non-Therapeutic
Experimentation', International Journal of
Law and Psychiatry, 20, pp. 113-39.
PART III RISK AND RESPONSIBILITY
21 Charles Weijer (2000), 'The Ethical 365(18)
Analysis of Risk', Journal of Law, Medicine
and Ethics, 28, pp. 344-61.
22 Nancy M.P. King (2000), 'Defining and 383(12)
Describing Benefit Appropriately in Clinical
Trials', Journal of Law, Medicine and Ethics,
28, pp. 332-43.
23 David Wendler (2002), 'What Research with 395(22)
Stored Samples Teaches us about Research with
Human Subjects', Bioethics, 16, pp. 33-54.
24 Robert J. Levine (1988), 'Uncertainty in 417(10)
Clinical Research', Law, Medicine and Health
Care, 16, pp. 174-82.
25 Benjamin Freedman (1987), 'Equipoise and 427(6)
the Ethics of Clinical Research', New England
Journal of Medicine, 317, pp. 141-115.
26 Richard Ashcroft (1999), 'Equipoise, 433(14)
Knowledge and Ethics in Clinical Research and
Practice', Bioethics, 13, pp. 314-26.
27 S. Senn (2002), 'Ethical Considerations 447(10)
Concerning Treatment Allocation in Drug
Development Trials', Statistical Methods in
Medical Research, 11, pp. 403-11.
28 Baruch A. Brody (1997), 'When are 457(14)
Placebo-Controlled Trials No Longer
Appropriate?', Control Clinical Trials, 18,
pp. 602-12.
PART IV GLOBALIZATION AND CORPORATION- TRUST
AND PARTICIPATION
29 Ruth Macklin (1999), 'International 471(26)
Research: Ethical imperialism or Ethical
Pluralism?, Accountability in Research, 7,
pp. 59-83.
30 Marcia Angell (2000), 'Is Academic 497(4)
Medicine for sale?', New England Journal of
Medicine, 342, pp. 1516-18.
31 James T. Rule and Adil E. Shamoo (1997), 501(12)
'Ethical Issues in Research Relationships
between Universities and Industry',
Accountability in Research, 5, pp. 239-49.
32 Thomas Bodenheimer (2000), 'Uneasy 513(6)
Alliance: Clinical Investigators and the
Pharmaceutical Industry', New England Journal
of Medicine, 342, pp. 1539-44.
33 Trudo Lemmens and Benjamin Freedman 519(38)
(2000), 'Ethics Review for Sale? Conflict of
Interest and Commercial Research Review
Boards', Milbank Quarterly Review, 78, pp.
547-84.
34 Jesse A. Goldner (2000), 'Dealing with 557(26)
Conflicts of Interest in Biomedical Research:
IRB Oversight as the Next Best Solution to
the Abolitionist Approach', Journal of Law,
Medicine and Ethics, 28, pp. 379-404.
35 Mark Yarborough and Richard R. Sharp 583(8)
(2002), 'Restoring and Preserving Trust in
Biomedical Research', Academic Medicine, 77,
pp. 8-14.
36 David B. Resnik (1999), 'Privatized 591(16)
Biomedical Research, Public Fears, and the
Hazards of Government Regulation: Lessons
from Stem Cell Research', Health Care
Analysis, 7, pp. 273-87.
Name index 607